ArticleJournal of diabetes and metabolic disorders2023

Empagliflozin improves high-sensitive cardiac troponin-I and high-density lipoprotein cholesterol in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD Trial.

Homa Taheri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.